Skip to Content

The Whistleblower Program under the Dodd-Frank and Foreign Corrupt Practices Acts

Section 922 of the Dodd-Frank Act - The Whistleblower Program

The Securities and Exchange Commission ("SEC") whistleblower program created under section 922 of the Dodd-Frank Act incentivizes those with knowledge of securities violations to "blow the whistle" on the person or company engaging in such conduct.

To initiate a suit, the whistleblower must complete and file a Form TCR (i.e., a Tip, Complaint or Referral Form), available on the SEC website detailing the violations and providing evidence and facts. If the SEC recovers money using the information the whistle blower provided, the whistleblower may apply for an award and stands to recover a portion of the money.

Contact For More Information (Green)

The Foreign Corrupt Practices Act

The anti-bribery provisions of the Foreign Corrupt Practices Act ("FCPA") make it unlawful to make a payment to a foreign official for the purpose of obtaining or retaining business for or with, or directing business to, any person.

The statute defines foreign official as "any officer or employee of a foreign government or any department, agency, or instrumentality thereof, or of a public international organization . . . ."  In other words, the FCPA includes in the definition of foreign official, "officers and employees of government instrumentalities."

While the FCPA does not define "instrumentality," the Department of Justice ("DOJ") and the SEC have construed "instrumentalities" broadly. The ability of the SEC and the DOJ to enforce the FCPA only extends to American companies and citizens who bribe foreign officials.

The Whistleblower Program under the Dodd-Frank Act and FCPA Whistleblowers

Because the SEC whistleblower program under the Dodd-Frank Act offers rewards for helping the government uncover securities violations, including violations of the FCPA, American companies who operate in foreign countries are coming under increased scrutiny.

American companies operating in the healthcare industry are particularly at risk because many conduct business in foreign countries with national healthcare systems that are run by the government and operated by government employees. The DOJ and the SEC interpret these government employees as "foreign officials" under the FCPA. Thus, when an American company offers these healthcare providers incentives for prescribing and ordering their medications, they risk violating the FCPA.

New settlements and awards related to the whistleblower program under Dodd-Frank for FCPA violations are emerging, indicating an increased use of the acts, and necessitating an increased awareness of them.

Contact Us To Learn More

Do you need a Whistleblower Lawyer or want to know more information about Qui Tam Law and your rights under the False Claims Act?

There are three easy ways to contact our firm:

  1. Use the contact form on this page ("Inquire About Your Potential Case")
  2. Email info@bm.net
  3. Call 888-647-9292

Your information will remain confidential and we will work to protect your rights.

Contact For More Information (Green)


What is Qui Tam Litigation?

Qui Tam eBook Button


Stay updated and follow us on:

Facebook

Facebook

Twitter

Twitter

LinkedIn

LinkedIn